UN torture expert warns over Assange extradition to US

WikiLeaks founder Julian Assange is seen as he leaves a police station in London, Britain April 11, 2019. (Reuters)
Updated 12 April 2019

UN torture expert warns over Assange extradition to US

EVILARD, Switzerland: Julian Assange is not guaranteed a fair trial in the United States, a UN rights expert told AFP Friday, questioning the US justice system’s credibility in national security cases.
The United Nations special rapporteur on torture and other cruel, inhuman or degrading treatment, Nils Melzer, also said that the manner in which Ecuador terminated Assange’s diplomatic protection broke international norms.
But Melzer made clear that his greatest concerns for the WikiLeaks founder — arrested by British police on Thursday after spending almost seven years in Ecuador’s London embassy — stem from Assange’s possible extradition to the US.
“I’m worried about fair trial,” said Melzer, one of several UN rapporteurs active on the Assange case.
“I’m worried that he might be exposed to (the) detention practices of the United States, which in part are very problematic,” he added.
“The United States in the last decade unfortunately has not proven to be a safe state with regard to the provision of torture in cases that involve national security,” Melzer added.
Melzer has previously raised alarm about alleged torture in the US detention facility at Guantanamo Bay, as well as over the use of waterboarding, which President Donald Trump has labelled an effective interrogation technique.
The US request to extradite Assange is set to be heard in British court on May 2.
US officials have unsealed an indictment against him for computer hacking as part of his WikiLeaks whistleblowing activities.
But Melzer echoed concerns that the US charge sheet could be expanded, especially if the Justice Department gets Assange on US soil.
The UN expert argued that regardless of one’s personal view of Assange, “from a human rights perspective, he was basically doing the same thing that investigative journalists do all over the world,” by publishing information that states try to conceal.
The national security implications of the charges, combined with the fact that the US practices the death penalty, is “obviously a very serious concern,” the UN expert further said.
Turning to the arrest, Melzer conceded that “theoretically” Ecuador had the right to terminate Assange’s protection and strip his citizenship.
“But in a state that is governed by the rule of law, these types of steps are to be taken in a procedure that is subject to legal remedies and appeals,” added Melzer, a Swiss national who also teaches international law at the University of Glasgow.
The “shortcuts” taken in the run up to the arrest are “very, very problematic,” he said.
“The rule of law is not being respected.”
Melzer, like all UN special rapporteurs, is an independent expert appointed by the Human Rights Council who does not speak for UN Secretary General Antonio Guterres.
Guterres’s top human rights official, High Commissioner Michelle Bachelet, has not condemned the arrest.
Bachelet’s spokeswoman, Ravina Shamdasani, told reporters in Geneva on Friday that the high commissioner expects “all relevant authorities to ensure that Mr. Assange’s right to a fair trial is upheld.”


UK to trial 5 new drugs in coronavirus fight

Updated 1 min 18 sec ago

UK to trial 5 new drugs in coronavirus fight

LONDON: British scientists are set to trial five new drugs in 30 hospitals across the country in the fight against the coronavirus disease (COVID-19).

The scientists are seeking hundreds of volunteers to take part in the trials for the new drugs, which they hope will reduce the need for intensive care treatment and the use of ventilators.

The new drugs include Heparin, which is used for blood thinning, and new medicines in clinical trials for conditions including muscular, lung and blood disorders, which have been shown to hold other antiviral and anti-inflammatory effects.

The tests will include the new medicine Medi3506, an anti-inflammatory injection developed for skin disorders and chronic obstructive pulmonary disease. It has also been used in trials for asthma by its producer AstraZeneca.

The studies are part of the Accord (accelerating COVID-19 research and development) program, which includes large swathes of Britain’s scientific research and development community, including workers from the National Health Service (NHS), the National Institute for Health Research (NHIR) and the UK Research and Innovation body.

“We are looking for a signal of both safety and efficacy, something that could reduce the severity of the disease, shorten its duration and prevent patients going into the intensive care environment,” said Tom Wilkinson, a respiratory medicine professor and consultant and the Accord academic lead, from the NIHR Southampton Biomedical Research Centre.

He added that the program is still searching for patients to join the trial, with few people currently signed up.

“These are small, rapidly deliverable studies if we get patients in, so we’re looking only to achieve around 60 patients for each arm of the trial to receive one of the drugs compared to usual standard of care,” he said.

The hospitals taking part in the trial include St. Thomas’ in London, where Prime Minister Boris Johnson was treated.

Other major hospitals in Liverpool, Manchester, Leeds, Leicester and Glasgow are also involved.

Coastal hospitals such as Southend are also participating amid concerns of new spikes emerging following crowded gatherings on beaches in recent weeks.